HER2 trial, trastuzumab serplulimab, biliary urothelial cancer
Summary
National Cancer Institute registered a Phase 2 clinical trial (NCT07506057) on ClinicalTrials.gov evaluating trastuzumab combined with serplulimab for HER2-positive biliary urothelial cancer. The study is sponsored by National Cancer Institute investigators and will assess safety and efficacy of this novel combination therapy in approximately 40 patients.
What changed
The National Cancer Institute registered a clinical trial (NCT07506057) on ClinicalTrials.gov testing trastuzumab combined with serplulimab in patients with HER2-positive biliary urothelial cancer. The trial is a Phase 2 study expected to enroll approximately 40 participants at NCI-affiliated clinical sites, with primary endpoints related to objective response rate and safety profile.
Healthcare institutions and clinical investigators at participating sites should review eligibility criteria for potential patient referrals. Trial sponsors must maintain accurate and complete registration information in compliance with FDAAA 801 requirements. Patients meeting inclusion criteria may be eligible for enrollment through participating oncology centers.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.